RxDoctor Payments Data

Julien Dagenais, MD

Urology · Denver, CONPI 1649579228

Payments from drug & device makers

What this record shows

This record is dominated by education: $7,560 of the $10,981 with a category attached, or 68.9%. Intuitive Surgical accounts for 83.3% of it on its own, with 18 other manufacturers making up the rest. 2025 is the largest year on record at $8,525, 8.7 times the $984 reported in 2019.

$10,981in general payments, 2019–2025

Across 110 payments — averaging $99.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$9K
  • Astellas Pharma US Inc$583
  • Johnson & Johnson$207
  • Endo Pharmaceuticals Inc.$177
  • Bayer$162
  • Myriad Genetic Laboratories, Inc.$117
  • plus $589 from 13 others

What the payments were for

  • Travel & lodging$1892%
  • Food & beverage$3,21129%
  • Education$7,56069%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,981 in reported general payments places this provider in the 80th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$139,263
Medicare patients
417
Services billed
4,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron34$33,235
GemtesaVibegron27$31,641
Tamsulosin Hcl300$3,839
Finasteride230$2,772
Testosterone19$2,291
Solifenacin Succinate48$2,194
Methenamine Hippurate13$1,733
Estradiol20$1,508
Fesoterodine Fumarate ErFesoterodine Fumarate13$1,482
Testosterone Cypionate26$1,000
Dutasteride26$867
Desmopressin Acetate12$420
Oxybutynin Chloride54$326
Alfuzosin Hcl ErAlfuzosin Hcl14$273
Ciprofloxacin Hcl28$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$583$33,23534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 urology providers in Colorado.

Other urology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →